Cost-effectiveness of universal childhood hepatitis A vaccination in Chile
| Author | dc.contributor.author | Valenzuela Bravo, María Teresa | |
| Author | dc.contributor.author | Jacobs, R. Jake | es_CL |
| Author | dc.contributor.author | Arteaga, Oscar | es_CL |
| Author | dc.contributor.author | Navarrete, María S. | es_CL |
| Author | dc.contributor.author | Meyerhoff, Allen S. | es_CL |
| Author | dc.contributor.author | Innis, Bruce L. | es_CL |
| Admission date | dc.date.accessioned | 2007-05-17T18:18:51Z | |
| Available date | dc.date.available | 2007-05-17T18:18:51Z | |
| Publication date | dc.date.issued | 2005-07-14 | |
| Cita de ítem | dc.identifier.citation | VACCINE | en |
| Identifier | dc.identifier.issn | 0264-410X | |
| Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/127164 | |
| Abstract | dc.description.abstract | A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts > 80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and > 4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile. | en |
| Lenguage | dc.language.iso | en | en |
| Publisher | dc.publisher | ELSEVIER SCI LTD | en |
| Keywords | dc.subject | COMMUNITY-WIDE OUTBREAK | en |
| Título | dc.title | Cost-effectiveness of universal childhood hepatitis A vaccination in Chile | en |
| Document type | dc.type | Artículo de revista |
Files in this item
This item appears in the following Collection(s)
-
Artículos de revistas
Artículos de revistas